Literature DB >> 13680286

Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up.

Katsuki Ito1, Hiroaki Nakazato, Akihiko Koike, Hiroshi Takagi, Shigetoyo Saji, Shozo Baba, Masayoshi Mai, Jun-ichi Sakamoto, Yasuo Ohashi.   

Abstract

BACKGROUND AND AIMS: The efficacy of a biological response modifier polysaccharide K in adjuvant immunochemotherapy was evaluated in primary colon cancer patients with macroscopic Dukes' C after curative resection. PATIENTS AND METHODS: Employing the minimization method using three factors (lymph node metastases, preoperative serum CEA level, and institution), 446 patients were allocated into groups P and C. Group P received immunochemotherapy, oral PSK (3 g per day) followed by oral 5-FU (200 mg/body per day), while group C received only intermittent chemotherapy, oral 5-FU (200 mg per day) followed by 4-week rest. Both groups received ten courses.
RESULTS: Survival for cancer death was significantly higher in group P than in group C, but there was no difference in 7-year disease-free survival or overall survival had.
CONCLUSION: Repeated alternating administration with PSK followed by 5-FU can improve survival for cancer death.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13680286     DOI: 10.1007/s00384-003-0532-x

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  21 in total

1.  Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group.

Authors: 
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

2.  Tables of the number of patients required in clinical trials using the logrank test.

Authors:  L S Freedman
Journal:  Stat Med       Date:  1982 Apr-Jun       Impact factor: 2.373

3.  Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer.

Authors:  S Tsujitani; Y Kakeji; H Orita; A Watanabe; S Kohnoe; H Baba; H Anai; Y Maehara; K Sugimachi
Journal:  Anticancer Res       Date:  1992 May-Jun       Impact factor: 2.480

4.  Immunotherapy and combined assay of serum levels of carcinoembryonic antigen and acute-phase reactants.

Authors:  K Ogoshi; M Miyaji; K Nakamura; Y Kondoh; H Makuuchi; T Tajima
Journal:  Cancer Immunol Immunother       Date:  1998-03       Impact factor: 6.968

5.  Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.

Authors: 
Journal:  Jpn J Clin Oncol       Date:  1995-06       Impact factor: 3.019

6.  The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer.

Authors:  C G Moertel; J R O'Fallon; V L Go; M J O'Connell; G S Thynne
Journal:  Cancer       Date:  1986-08-01       Impact factor: 6.860

7.  Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin 2.

Authors:  Y Kariya; N Inoue; T Kihara; N Okamoto; K Sugie; T Mori; A Uchida
Journal:  Immunol Lett       Date:  1992-02-15       Impact factor: 3.685

8.  Polysaccharide preparation PSK augments the proliferation and cytotoxicity of tumor-infiltrating lymphocytes in vitro.

Authors:  K Noguchi; H Tanimura; H Yamaue; T Tsunoda; M Iwahashi; M Tani; S Mizobata; T Hotta; K Arii; M Tamai
Journal:  Anticancer Res       Date:  1995 Mar-Apr       Impact factor: 2.480

9.  Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide.

Authors:  M Kato; K Hirose; M Hakozaki; M Ohno; Y Saito; R Izutani; J Noguchi; Y Hori; S Okumoto; D Kuroda
Journal:  Cancer Immunol Immunother       Date:  1995-03       Impact factor: 6.968

10.  Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa).

Authors:  T Mitomi; S Tsuchiya; N Iijima; K Aso; K Suzuki; K Nishiyama; T Amano; T Takahashi; N Murayama; H Oka
Journal:  Dis Colon Rectum       Date:  1992-02       Impact factor: 4.585

View more
  8 in total

1.  Phase III trial comparing UFT + PSK to UFT + LV in stage IIB, III colorectal cancer (MCSGO-CCTG).

Authors:  Yasuhiro Miyake; Junichi Nishimura; Takeshi Kato; Masataka Ikeda; Masaki Tsujie; Taishi Hata; Ichiro Takemasa; Tsunekazu Mizushima; Hirofumi Yamamoto; Mitsugu Sekimoto; Riichiro Nezu; Yuichiro Doki; Masaki Mori
Journal:  Surg Today       Date:  2017-06-20       Impact factor: 2.549

Review 2.  Possible mechanisms of action of mushroom-derived glucans on inflammatory bowel disease and associated cancer.

Authors:  Betty Schwartz; Yitzhak Hadar
Journal:  Ann Transl Med       Date:  2014-02

Review 3.  Immunomodulatory dietary polysaccharides: a systematic review of the literature.

Authors:  Jane E Ramberg; Erika D Nelson; Robert A Sinnott
Journal:  Nutr J       Date:  2010-11-18       Impact factor: 3.271

Review 4.  Trametes versicolor mushroom immune therapy in breast cancer.

Authors:  Leanna J Standish; Cynthia A Wenner; Erin S Sweet; Carly Bridge; Ana Nelson; Mark Martzen; Jeffrey Novack; Carolyn Torkelson
Journal:  J Soc Integr Oncol       Date:  2008

Review 5.  Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives.

Authors:  Yoshihiko Maehara; Shunichi Tsujitani; Hiroshi Saeki; Eiji Oki; Keiji Yoshinaga; Yasunori Emi; Masaru Morita; Shunji Kohnoe; Yoshihiro Kakeji; Tokujiro Yano; Hideo Baba
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

6.  Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial).

Authors:  Kiyotaka Okuno; Toru Aoyama; Koji Oba; Noboru Yokoyama; Nobuhisa Matsuhashi; Katsuyuki Kunieda; Yoji Nishimura; Hiroki Akamatsu; Takaya Kobatake; Satoshi Morita; Takaki Yoshikawa; Junichi Sakamoto; Shigetoyo Saji
Journal:  Cancer Chemother Pharmacol       Date:  2017-11-01       Impact factor: 3.333

7.  Can polysaccharide K improve therapeutic efficacy and safety in gastrointestinal cancer? a systematic review and network meta-analysis.

Authors:  Yan Ma; Xiaofen Wu; Jingwen Yu; Jinyan Zhu; Xia Pen; Xianjun Meng
Journal:  Oncotarget       Date:  2017-07-06

8.  Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer.

Authors:  C Alliot
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.